ghrelin and glp-1 Is a glucagon‐like peptide‐1 secretagogue? - Ueno - 2016 - Journal of Diabetes Investigation Figure 1 from Ghrelin, CCK,

Retatrutide: Phase 2 and TRIUMPH results Retatrutide clinical data comes from two major sources: the Phase 2 obesity trial published in the New England Journal of Medicine, and the recently announced Phase 3 TRIUMPH-4 results

But for the right patients, combined with comprehensive support, they can be genuinely helpful for both weight and mental health

Weve found that people generally tolerate GLP-1 for weight loss well, and the side effect profile seems to be fairly mild and predictable

Injecting too fast forces a large bolus of liquid into a small subcutaneous space, which can cause pain, lump formation, and potentially altered absorption kinetics

It is crucial to understand that microdosing is not a licensed or evidence-based approach to GLP-1 therapy